ISR
Latest Trade
0.66USDChange
0.01(+2.06%)Volume
349,201Today's Range
-
0.6852 Week Range
-
0.78As of on the NYSE MKT LLC ∙ Minimum 15 minute delay
Previous Close | 0.65 |
|---|---|
Open | 0.64 |
Volume | 349,201 |
3M AVG Volume | 7.29 |
Today's High | 0.68 |
Today's Low | 0.62 |
52 Week High | 0.78 |
52 Week Low | 0.27 |
Shares Out (MIL) | 67.39 |
Market Cap (MIL) | 44.46 |
Forward P/E | -11.64 |
Dividend (Yield %) | -- |
IsoRay Q1 Revenue Rose 48 Percent To $2.32 Million
IsoRay Reports Q4 Loss Per Share $0.02
IsoRay Files Prospectus Relating To Offering & Resale By Selling Stockholders Of Up To 5.8 Mln Shares
IsoRay, Inc. is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc., develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds. Brachytherapy seeds are small devices containing a therapeutic dose of radiation used in an interstitial radiation procedure. The brachytherapy procedure places radioactive seeds as close as possible to (in or near) the cancerous tumor. The Cs-131 includes radioisotope in the treatment of all malignant tumors, such as prostate cancer, brain cancer, breast cancer, colorectal cancer, gynecological cancer, lung cancer, liver cancer, ocular melanoma and pancreatic cancer. The Company's Proxcelan Cesium-131 seed is classified as a Class II device.
Industry
Medical Equipment & Supplies
Executive Leadership
Michael W. McCormick
Chairman of the Board, Director
Lori A. Woods
Interim Chief Executive Officer, Director
Jennifer Streeter
Interim Chief Operating Officer, Vice President of Human Resources
Mark John Austin
Principal Accounting Officer, Co-Principal Financial Officer, Controller
Michael Krachon
Vice President, Director of Sales and Marketing
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 5.51 |
Price To Book (MRQ) | 6.39 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 3.24 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -44.16 |
Return on Equity (TTM) | -37.94 |
* ISORAY ANNOUNCES THE FIRST DISPOSABLE DELIVERY SYSTEM FOR CUSTOM INTRA-OPERATIVE STRANDS FOR PROSTATE CANCER TREATMENT Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)
* ISORAY INC - ON MAY 8, 2018, CO ENTERED INTO A SALES AGREEMENT WITH H.C. WAINWRIGHT & CO., LLC - SEC FILING
* ISORAY ANNOUNCES THIRD QUARTER FISCAL 2018 REVENUE OF $1.57 MILLION, 23 PCT THIRD QUARTER-OVER-THIRD QUARTER INCREASE
* ISORAY ANNOUNCES SECOND QUARTER FISCAL 2018 REVENUE OF $1.54 MILLION, 50 PCT SECOND QUARTER-OVER-SECOND QUARTER INCREASE
* ISORAY ANNOUNCES PRELIMINARY SECOND QUARTER F2018 REVENUE OF $1.54 MILLION, 50% YEAR-OVER-YEAR INCREASE
* ISORAY SAYS ON DEC 29, 2017, CO NOTIFIED AL & J MEDIA INC OF ITS DECISION TO TERMINATE MEDIA ADVERTISING AGREEMENT BETWEEN PARTIES - SEC FILING Source text: (http://bit.ly/2CTpIiQ) Further company coverage:
* IsoRay announces first quarter fiscal 2018 financial results
* Announces the launch of a Phase II, multicenter clinical trial with Cesium-131 adjuvant radiation for Retroperitoneal Sarcoma Delivery System (Cards Trial) by University of Louisville, division of surgical oncology Source text for Eikon: Further company coverage:
* Isoray announces fourth quarter fiscal 2017 revenue of $1.37 million, 22 pct fourth quarter-over-fourth quarter increase
* Isoray says on Aug 25, Isoray Medical, a unit of co, entered into a consignment agreement with Medikorpharma-Ural LLC - SEC filing
* Isoray receives FDA response to 510(k) application for Gammatile
* Isoray announces third quarter fiscal 2017 financial results
* Isoray announces final court approval of class action settlement Source text for Eikon: Further company coverage:
* Says continues to expect stronger second half of fiscal 2017
* Isoray Inc -on January 16, 2017, Brien Ragle, CFO of co, informed board of his resignation from all positions held with co and its subsidiaries, effective immediately
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.